Cim Investment Mangement Inc. reduced its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,904 shares of the biopharmaceutical company’s stock after selling 66 shares during the period. Cim Investment Mangement Inc.’s holdings in Alexion Pharmaceuticals were worth $597,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after buying an additional 17,960,356 shares during the last quarter. Bank of Montreal Can increased its position in shares of Alexion Pharmaceuticals by 628.8% in the second quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock valued at $173,174,000 after buying an additional 1,228,025 shares during the last quarter. Bessemer Group Inc. increased its position in shares of Alexion Pharmaceuticals by 1,949,640.5% in the second quarter. Bessemer Group Inc. now owns 721,404 shares of the biopharmaceutical company’s stock valued at $87,772,000 after buying an additional 721,367 shares during the last quarter. State Street Corp increased its position in shares of Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after buying an additional 718,756 shares during the last quarter. Finally, Marshall Wace North America L.P. bought a new position in shares of Alexion Pharmaceuticals during the first quarter valued at approximately $65,219,000. 94.26% of the stock is owned by institutional investors and hedge funds.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 138.82 on Thursday. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $145.41. The firm has a 50-day moving average of $132.60 and a 200-day moving average of $123.39. The firm has a market capitalization of $30.98 billion, a PE ratio of 60.20 and a beta of 1.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business had revenue of $912 million during the quarter, compared to the consensus estimate of $846.15 million. During the same period last year, the company earned $1.13 earnings per share. The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. Equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Cim Investment Mangement Inc. Lowers Position in Alexion Pharmaceuticals, Inc. (ALXN)” was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.watchlistnews.com/cim-investment-mangement-inc-lowers-position-in-alexion-pharmaceuticals-inc-alxn/1534135.html.

Several equities analysts recently commented on ALXN shares. Morgan Stanley raised shares of Alexion Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $101.08 to $138.00 in a research note on Thursday, May 25th. Barclays PLC reissued an “overweight” rating and issued a $155.00 price objective on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 9th. Cowen and Company reissued an “outperform” rating and issued a $122.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, July 3rd. J P Morgan Chase & Co downgraded shares of Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Tuesday, May 23rd. Finally, SunTrust Banks, Inc. reissued a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. Six research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $156.13.

In related news, EVP Julie O’neill sold 11,160 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares in the company, valued at $3,738,560. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the completion of the sale, the director now owns 6,315 shares of the company’s stock, valued at $869,828.10. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 2,019,734 shares of company stock valued at $235,606,846. Corporate insiders own 4.35% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.